modelFructose
Extends from Pharmacolibrary.Drugs.ATC.V.V06DC02.
Information
| name: | Fructose | |
| ATC code: | V06DC02 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 25000 | mg |
| volume of distribution: | 0.2 | L |
| clearance: | 1.5 | L/h/kg |
| other parameters in model implementation | ||
Fructose is a simple monosaccharide sugar commonly used as a sweetener in foods and is an ingredient in various intravenous infusion preparations, mainly as a component of parenteral nutrition solutions. Clinically, fructose solutions have been used in the past for energy supply, especially in patients requiring intravenous feeding. Its use is now limited, and it is not commonly used as a primary therapeutic agent due to concerns over its metabolic processing and adverse effects in some populations.
Pharmacokinetics
Pharmacokinetic parameters for intravenous administration in healthy adult volunteers; values are estimated based on published information for similar infusion solutions due to absence of direct clinical pharmacokinetic studies.
References
Yoon, Y, & Jagoda, A (2000). New antiepileptic drugs and preparations. Emergency medicine clinics of North America 18(4) 755–765. DOI:10.1016/s0733-8627(05)70157-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11130937
Ahmed, GF, et al., & Birnbaum, AK (2015). Pharmacokinetic-pharmacodynamic modelling of intravenous and oral topiramate and its effect on phonemic fluency in adult healthy volunteers. British journal of clinical pharmacology 79(5) 820–830. DOI:10.1111/bcp.12556 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25403343
Lim, CN, et al., & Marino, SE (2016). Pharmacokinetic-Pharmacodynamic Modeling of Intravenous and Oral Topiramate and Its Effect on the Symbol-Digit Modalities Test in Adult Healthy Volunteers. Journal of clinical pharmacology 56(6) 714–722. DOI:10.1002/jcph.646 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26395889
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)